SAGE-324 was being developed by Biogen for the treatment of essential tremor.[4] Its development was discontinued in 2024 due to lack of efficacy in Phase 2 clinical trials.[5]
↑Quagliato, Laiana A.; Carta, Mauro G.; Nardi, Antonio E. (September 2022). "Panic Disorder Seeks More Specific Drugs for Treatment: Might the Amygdala Be the Best Target?". Journal of Clinical Psychopharmacology. 42 (5): 427–428. doi:10.1097/JCP.0000000000001591. PMID36099401. S2CID252219658.